NRX Pharmaceuticals Inc
NASDAQ:NRXP
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
NRX Pharmaceuticals Inc
NASDAQ:NRXP
|
66.3m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
934.5B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
256.6B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.5B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
235B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
285.6B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.3B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.2B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
NRX Pharmaceuticals Inc
Glance View
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. NRX-101 is a fixed-dose combination of D-cycloserine and lurasidone for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB). Its ZYESAMI (aviptadil) is an investigational drug for COVID-19-related respiratory failure. The firm has completed a Phase IIb/III clinical study in patients with acute respiratory failure in COVID-19.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for NRX Pharmaceuticals Inc is 59.9%, which is in line with its 3-year median of 59.9%.
Over the last 0 months, NRX Pharmaceuticals Inc’s Gross Margin has decreased from 59.9% to 59.9%. During this period, it reached a low of 59.9% on Oct 30, 2025 and a high of 59.9% on Oct 30, 2025.
